Analysts Set NewLink Genetics Corp (NLNK) PT at $4.75
Shares of NewLink Genetics Corp (NASDAQ:NLNK) have been given a consensus recommendation of “Hold” by the nine brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $4.75.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded NewLink Genetics from a “hold” rating to a “strong-buy” rating and set a $2.50 price target for the company in a report on Wednesday, November 7th. Bank of America lowered their price objective on NewLink Genetics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, November 2nd. Finally, Stifel Nicolaus downgraded NewLink Genetics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $8.00 to $4.00 in a research note on Wednesday, August 1st.
NLNK stock traded up $0.25 during midday trading on Monday, hitting $2.11. 451,160 shares of the company’s stock were exchanged, compared to its average volume of 740,449. NewLink Genetics has a 12-month low of $1.84 and a 12-month high of $10.41. The company has a market capitalization of $73.71 million, a PE ratio of -0.92 and a beta of 1.55.
A number of hedge funds have recently made changes to their positions in the business. Quantitative Systematic Strategies LLC acquired a new stake in shares of NewLink Genetics during the second quarter worth $133,000. Pennsylvania Trust Co bought a new stake in shares of NewLink Genetics during the 2nd quarter worth about $395,000. Russell Investments Group Ltd. bought a new stake in shares of NewLink Genetics during the 3rd quarter worth about $219,000. Acadian Asset Management LLC bought a new stake in shares of NewLink Genetics during the 2nd quarter worth about $1,231,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of NewLink Genetics by 432.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 286,338 shares of the biotechnology company’s stock worth $684,000 after acquiring an additional 232,530 shares in the last quarter. Institutional investors own 41.95% of the company’s stock.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
Further Reading: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.